A ruling against skinny labeling could push back generic drug competition by years, with billions in costs passed on to ...
The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results